From: Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
Effect | Maximum likelihood estimates | ||||
---|---|---|---|---|---|
Parameter | Week 24 | Week 48 | |||
Estimate a | Pr > ChiSq | Estimate a | Pr > ChiSq | ||
‘Improvers’ | |||||
Treatmentb | Treatment 9.5 mg/24 h patch | −0.580 | 0.0001 | −0.461 | 0.021 |
Gender | Female | 0.234 | 0.137 | −0.040 | 0.014 |
ADAS-cogc | ADAS-cogc | 0.044 | 0.017 | −0.438 | 0.059 |
ADCS-IADLc | ADCS-IADLc | −0.026 | 0.050 | na | na |
MMSEc | MMSE ≤12c | −0.854 | <0.0001 | na | na |
‘Non-decliners’ | |||||
Treatmentb | Treatment 9.5 mg/24 h patch | −0.337 | 0.002 | −0.270 | 0.058 |
Gender | Female | 0.218 | 0.094 | na | na |
ADAS-cogc | ADAS-cogc | 0.031 | 0.014 | na | na |
ADCS-IADLc | ADCS-IADLc | na | na | −0.027 | 0.020 |
MMSEc | MMSE ≤12c | −0.497 | 0.002 | −0.351 | 0.040 |
Weight, versus >80 kg | Weight 50 to 80 kg | −0.363 | 0.068d | −0.405 | 0.119d |
Weight <50 kg | 0.208 | 0.344 |